FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi
The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration on Friday approved medicines from AbbVie and Pfizer for the treatment of eczema. AbbVie's Rinvoq and Pfizer's Cibinqo each work by suppressing Janus kinases, or JAKs, a group of proteins that regulate the immune system and inflammation. Rinvoq had previously been cleared by the FDA to treat two kinds of arthritis, whereas Friday's approval was the first for Cibinqo in the U.S. Both AbbVie's and Pfizer's drugs are taken orally, a convenience which could eventually help them compete against injectable eczema treatments like Sanofi and Regeneron's Dupixent. Over the first nine months of 2021, Sanofi recorded 3.7 billion euros
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
